BARDA awards Altimmune anthrax contract

Altimmune Inc. (Gaithersburg, Md.) said HHS's Biomedical Advanced Research and Development Authority (BARDA) awarded it a contract for up to $120.2 million to fund clinical development of anthrax vaccine candidate NasoShield (formerly AdVAV anthrax vaccine).

The five-year contract provides $14.3 million to fund a Phase I trial of NasoShield that is scheduled to begin in 2H17, with options for an additional $105.9 million that would fund further development. ...